^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tevimbra (tislelizumab-jsgr)

    i
    Other names: BGB-A317, BGB A317, VDT482, BGBA317, VDT 482, VDT-482
    Company:
    BeOne Medicines
    Drug class:
    PD1 inhibitor
    Related drugs:
    19h
    Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Shanghai Changzheng Hospital
    New P1 trial
    |
    Tevimbra (tislelizumab-jsgr) • triptorelin • goserelin acetate
    22h
    A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 04] (clinicaltrials.gov)
    P2, N=110, Not yet recruiting, Nanjing Leads Biolabs Co.,Ltd
    New P2 trial
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    2d
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. (clinicaltrials.gov)
    P3, N=752, Not yet recruiting, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    HER-2 negative • HER-2 expression • CLDN18.2 positive • CLDN1 positive
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • tecotabart vedotin (LM-302)
    2d
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC (clinicaltrials.gov)
    P2, N=94, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)
    3d
    Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, Shanghai Huaota Biopharmaceutical Co., Ltd.
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed
    4d
    SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2/3, N=30, Recruiting, Second Affiliated Hospital of Nanchang University | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Apr 2025
    Enrollment open • Trial initiation date
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed
    4d
    The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities (clinicaltrials.gov)
    P2, N=66, Not yet recruiting, First Affiliated Hospital of Wenzhou Medical University
    New P2 trial • Checkpoint inhibition
    |
    Tecentriq (atezolizumab) • Tevimbra (tislelizumab-jsgr) • ondansetron
    5d
    Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=69, Recruiting, Oncomatryx Biopharma S.L.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • OMTX705
    6d
    Clinical trial of safety, tolerability and preliminary efficacy of crept-618 combined with tirelizumab injection in the treatment of unresectable hepatocellular carcinoma (ChiCTR2600117700)
    P=N/A, N=10, Not yet recruiting, People's Hospital of Deyang City; People's Hospital of Deyang City
    New trial
    |
    MUC4 (Mucin 4, Cell Surface Associated)
    |
    Tevimbra (tislelizumab-jsgr)
    6d
    TACE Combined with Tislelizumab and Lenvatinib in the Treatment of Unresectable Hepatocellular Carcinoma: A Randomized Controlled Clinical Study (ChiCTR2600117605)
    P=N/A, N=120, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New trial
    |
    Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)
    6d
    A multicenter, prospective, observational cohort study comparing lenvatinib mesylate and tislelizumab in combination with RALOX-HAIC versus combination with FOLFOX-HAIC for the treatment of advanced hepatocellular carcinoma (ChiCTR2600117082)
    P=N/A, N=444, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
    New trial
    |
    5-fluorouracil • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • leucovorin calcium
    6d
    Efficacy and Safety Study of Oral Paclitaxel Solution Combined with Tislelizumab and Cetuximab as Neoadjuvant Therapy in Elderly Patients with Platinum-Intolerant Head and Neck Squamous Cell Carcinoma (ChiCTR2600116935)
    P=N/A, N=60, Not yet recruiting, Shanghai Ninth People's Hospital; Shanghai Ninth People's Hospital
    New trial
    |
    Erbitux (cetuximab) • paclitaxel • Tevimbra (tislelizumab-jsgr)